Scott Foraker News Today

Learn about Agoura Hills-based biotech company A2 Biotherapeutics Inc., which has begun clinical trials for the first drug derived from its cell therapy drug platform.

The first patient has been dosed with the autologous CAR T-cell therapy A2B530 in the multicenter, first-in-human, phase 1/2 EVEREST-1 study.

A2 Biotherapeutics adding second site in the city, part of the Conejo Valley life sciences hub.

/PRNewswire/ -- A2 Biotherapeutics, Inc., "A2 Bio", is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid...

Agoura Hills biotech company A2 Biotherapeutics on Wednesday announced it has entered into a collaboration agreement with pharma giant Merck to further develop its cancer therapies. According to the agreement, A2 will receive an unspecified upfront payment, as well as milestone payments and royalties on sales of any approved product. Equity investment and reimbursement of some expenses will be available to the Agoura Hills company. Terms indicate A2 will continue its research and development of...

A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers Deal enables A2 to build allogeneic capability News provided by Share this article Share this article AGOURA HILLS, Calif., Dec. 23, 2020 /PRNewswire/ -- A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, today announced that it has entered into an agreement with Merck, known as MSD outs...